Contemporary management of endometrial cancer (Q37996608)

26 August 2017

Contemporary management of endometrial cancer (English)

1 reference

26 August 2017

3

Jalid Sehouli

0 references

Jason D Wright

series ordinal

1

object named as

Jason D Wright

1 reference

26 August 2017

4

Keiichi Fujiwara

1 reference

26 August 2017

Nicanor I Barrena Medel

series ordinal

2

1 reference

PubMed ID

22444602

26 August 2017

Thomas J Herzog

series ordinal

5

1 reference

PubMed ID

22444602

26 August 2017

language of work or name

English

0 references

publication date

22 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

379

1 reference

26 August 2017

9823

1 reference

26 August 2017

1352-1360

1 reference

Global cancer statistics, 2002

26 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

1 reference

7 January 2021

Geographic and temporal variations in cancer of the corpus uteri: Incidence and mortality in pre- and postmenopausal women in Europe

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Hormone replacement therapy and endometrial cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Risk of Endometrial Cancer Following Estrogen Replacement With and Without Progestins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Prospective Determination of Prevalence of Lynch Syndrome in Young Women With Endometrial Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Cancer risk in mutation carriers of DNA-mismatch-repair genes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Cancer risk associated with germline DNA mismatch repair gene mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Adjuvant hormone therapy of primary endometrial carcinoma with oxyprogesterone caproate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Risk factors and recurrent patterns in Stage I endometrial cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Significance of pathologic patterns of pelvic lymph node metastases in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Stage IIIC endometrioid corpus cancer includes distinct subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Surgical stage I endometrial cancer: predictors of distant failure and death

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Assessment of depth of myometrial invasion in endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Surgical staging for patients presenting with grade 1 endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

The impact of complete surgical staging on adjuvant treatment decisions in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Systematic pelvic and aortic lymphadenectomy in intermediate and high-risk endometrial cancer: lymph-node mapping and identification of predictive factors for lymph-node status

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Retrospective Analysis of Selective Lymphadenectomy in Apparent Early-Stage Endometrial Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Improving sentinel lymph node detection rates in endometrial cancer: how many cases are needed?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Laparoscopically assisted surgical staging (LASS) of endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Safety of laparoscopy versus laparotomy in early-stage endometrial cancer: a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Quality of life after total laparoscopic hysterectomy versus total abdominal hysterectomy for stage I endometrial cancer (LACE): a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Quality of life of patients with endometrial cancer undergoing laparoscopic international federation of gynecology and obstetrics staging compared with laparotomy: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

A comparative study of 3 surgical methods for hysterectomy with staging for endometrial cancer: robotic assistance, laparoscopy, laparotomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Comprehensive surgical staging for endometrial cancer in obese patients: comparing robotics and laparotomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Endometrial cancer surgery costs: robot vs laparoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Ovarian preservation during the surgical treatment of early stage endometrial cancer: A nation-wide study conducted by the Korean Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Ovarian preservation and staging in reproductive-age endometrial cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Safety of ovarian preservation in premenopausal women with endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Adenocarcinoma of the endometrium treated with combined irradiation and surgery: study of 437 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Conservative management of stage I endometrial carcinoma after surgical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: A Japanese Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Frequency and effect of adjuvant radiation therapy among women with stage I endometrial adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Acute toxicity of postoperative IMRT and chemotherapy for endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Final analysis of RTOG 9708: Adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Survival after relapse in patients with endometrial cancer: results from a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Salvage cytoreductive surgery for recurrent endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Management of recurrent endometrioid endometrial carcinoma: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Hormone therapy in advanced and recurrent endometrial cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Systematic review of systemic therapy for advanced or recurrent endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Paclitaxel and Cisplatin in Advanced or Recurrent Carcinoma of the Endometrium: Long-Term Results of a Phase II Multicenter Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

Clinical and biological significance of vascular endothelial growth factor in endometrial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2812%2960442-5

7 January 2021

10.1016/S0140-6736(12)60442-5

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22444602